Cardiovascular disease prevention may gain a powerful new tool through targeted delivery of plant compounds that precisely modulate cholesterol metabolism at the cellular level. This advancement could transform how millions manage hypercholesterolemia without relying solely on statins.
Researchers demonstrated that fisetin, a flavonoid found in strawberries and other fruits, significantly reduces total cholesterol, triglycerides, and LDL cholesterol in hypercholesterolemic mice. The compound targets asialoglycoprotein receptor 1 (ASGR1) in liver cells, triggering a cascade through the mTORC1/AMPK pathway that upregulates cholesterol excretion proteins including ABCA1, ABCG5, and CYP7A1 while modulating metabolism regulators like HMGCR and LDLR. Crucially, when ASGR1 was overexpressed, fisetin's cholesterol-lowering effects were blocked, confirming this receptor as the primary target. The team engineered carboxymethyl chitosan-modified β-cyclodextrin nanoparticles that delivered fisetin at one-fifth the concentration of free compound while achieving equivalent cholesterol reduction.
This work addresses a critical gap in natural product therapeutics, where promising compounds often fail due to poor bioavailability. Previous fisetin research has shown antioxidant and anti-inflammatory properties, but clinical applications remained limited by solubility issues. The ASGR1 pathway discovery is particularly significant because it represents a novel cholesterol regulation mechanism distinct from statin targets. The nanoparticle formulation overcomes traditional delivery challenges while potentially reducing side effects through lower dosing requirements. However, the study's limitation to mouse models necessitates human trials to validate efficacy and safety. This targeted delivery approach could herald a new generation of precision nutraceuticals for metabolic disorders.
